KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Current Assets: 2017-2024

Historic Current Assets for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to $88.2 million.

  • Aquestive Therapeutics' Current Assets rose 57.06% to $151.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $151.7 million, marking a year-over-year increase of 57.06%. This contributed to the annual value of $88.2 million for FY2024, which is 115.35% up from last year.
  • Latest data reveals that Aquestive Therapeutics reported Current Assets of $88.2 million as of FY2024, which was up 115.35% from $41.0 million recorded in FY2023.
  • In the past 5 years, Aquestive Therapeutics' Current Assets ranged from a high of $88.2 million in FY2024 and a low of $39.9 million during FY2022.
  • Moreover, its 3-year median value for Current Assets was $41.0 million (2023), whereas its average is $56.4 million.
  • As far as peak fluctuations go, Aquestive Therapeutics' Current Assets slumped by 34.68% in 2020, and later spiked by 115.35% in 2024.
  • Yearly analysis of 5 years shows Aquestive Therapeutics' Current Assets stood at $44.6 million in 2020, then climbed by 5.90% to $47.3 million in 2021, then dropped by 15.60% to $39.9 million in 2022, then increased by 2.70% to $41.0 million in 2023, then soared by 115.35% to $88.2 million in 2024.